(UroToday.com) The 2026 European Association of Urology (EAU) annual meeting featured an advancement in metastatic castration resistant prostate cancer (mCRPC) therapy session and a presentation by Dr ...

Multicancer assays leverage cfDNA methylation patterns to detect malignancy and infer tumor origin, with reported tissue-of-origin prediction approaching 87% accuracy in real-world experience. The 142 ...

Australian scientists say it could also help reduce the risk of overdiagnosis by determining which cancers are low-risk and will never cause harm.

Prostate cancer is one of the most common cancers affecting men around the world. It develops in the prostate, a small gland ...

A scan that makes prostate cancer cells “glow” could halve the number of men needing invasive biopsies, research suggests.

First results of the PRIMARY2 randomized phase III trial support consideration of PSMA PET/CT in diagnostic work-up ...

New findings from the phase III PRIMARY2 trial presented at EAU26 suggest that PSMA PET/CT imaging after inconclusive or reassuring MRI can safely reduce prostate biopsies by about 50 percent without ...

Men could soon be offered quick MRI scans lasting under 15 minutes to detect prostate cancer earlier, under new ...

Urologists, radiologists and pathologists from Europe and the US agreed an “expert consensus statement” on prostate cancer treatment and diagnosis ...

We’re prostate cancer experts. Here are the benefits of quick and targeted MRI scans - Urologists, radiologists and pathologists from Europe and the US agreed an “expert consensus statement” on prosta ...